Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
April 05, 2017 12:00 AM

Gottlieb favors regulations that empower doctors while keeping FDA standards

Virgil Dickson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Associated Press

    Dr. Scott Gottlieb Wednesday said he believes the federal government can speed up the approval of new drugs and devices while maintaining standards and leaving decisionmaking in the hands of clinicians.

    President Donald Trump's pick for top federal drug and device regulator said faster product approval benefits both patients and physicians. But some of Gottlieb's responses during his confirmation hearing before the Senate Committee on Health, Education, Labor and Pensions alarmed those who say his deep ties to the pharmaceutical industry will cause a conflict of interest.

    Gottlieb, a practicing internist in Stamford, Conn., and health industry consultant has for years criticized the FDA regulatory process as too burdensome.

    Sen. Elizabeth Warren (D-Mass.) brought up a 2012 Gottlieb penned for the conservative journal National Affairs where he noted a trend in which the FDA has rejected drugs over fears of off-label use.

    For instance, a painkiller Arcoxia was rejected in April 2007 because of the concern that it could increase the risk of heart attack and stroke with prolonged use. But the drug was meant for short-term pain relief.

    Gottlieb argued in the piece that the FDA did not trust doctors to make those decisions. Warren thought it appeared Gottlieb was against strong consumer protections.

    Gottlieb said what he meant to stress was clinician empowerment.

    “My concern that the agency was losing confidence in physicians and felt it need to step into, through regulation, into the practice of medicine to try to supplant their judgment for the judgment of doctors,” Gottlieb said.

    Adding to concerns over patient protections, Sen. Richard Burr, (R-N.C) asked Gottlieb whether he thought the clinical trial process was burdensome to physicians.

    “In 2017, should there still be double blind studies where the doctor doesn't even know if the patient is getting a placebo or not?,” Burr said.

    Gottlieb responded the FDA should consider multiple new clinical trial standards to bring innovative products to the market without sacrificing safety and efficacy standards.

    “I cannot think of any alternative study design that is superior to a randomized trial in terms of minimizing the chance of selection bias,” said Kay Dickersin, director of the Center for Clinical Trials and Evidence Synthesis at Johns Hopkins Bloomberg School of Public Health.

    Dr. Richard Friedman, a clinical trial expert and professor of clinical psychiatry at Weill Cornell Medical College said it was “alarming” to hear Gottlieb's position, adding that “it would put the public at serious potential risk, elevating the financial interests of the drug companies over public health.”

    In a conflict of interest notice released by the Trump administration, Gottlieb noted that he had advisory or financial connections to about 30 drug, diagnostic and device companies, including GlaxoSmithKline.

    Senate Democrats raised serious concerns about those ties and the fact that Gottlieb has invested in have more than 60 drugs that could come before the FDA for approval in the future. He has also worked for companies that have interest in over 120 drugs that are currently being tested.

    Trump has chosen “profoundly conflicted appointees”, according to Norman Eisen, former special counsel to President Barack Obama.

    HHS Secretary Tom Price also was criticized during his confirmation process for introducing legislation that would benefit companies he held stocks in when he was a congressman.

    Republicans, such as HELP committee chair Sen. Lamar Alexander, noted that Dr. Robert Califf, the final FDA Commissioner under Obama also was friendly with the industry.

    Alexander (R-Tenn.) said he believed that history benefits FDA commissioners.

    “I'm glad to know that you got a background and experience in the issues before you,” Alexander said to Gottlieb at the hearing.

    Gottlieb, 44, was a deputy commissioner of the FDA under President George W. Bush.

    He said his first priority will be tackling the opioid epidemic which he said was a serious public health issue on par with infectious diseases like Ebola or Zika. He said solutions will "require dramatic action," including finding ways to spur development of non-addictive alternative painkillers as well as addiction treatments.

    A committee vote on Gottlieb's nomination is expected after the Easter recess Alexander said.

    The Associated Press contributed to this report.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    congress prescription drugs
    PBMs, Big Pharma face off in House hearing
    Biden COVID copy_i_i.jpg
    Biden administration asks employers to help more workers who lose Medicaid
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing